跳至主要内容
临床试验/NCT05089357
NCT05089357已完成不适用

A Prospective, Non-interventional Study to Collect Subject and Physician Satisfaction During Long Term Treatment of Glabellar Lines With Dysport® in Subjects of Chinese Origin in Real Clinical Practice

Galderma R&D1 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2021年11月11日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Galderma R&D
入组人数
250
试验地点
1
主要终点
Percentage of Participants in Each Response Category for Overall Participant Satisfaction at Visit 6, Assessed by the Subject Satisfaction Questionnaire

研究概览

简要总结

This is a prospective, longitudinal, non-interventional, multi-center study to collect subject and physician satisfaction, and treatment experience with Dysport in real clinical practice in subjects of Chinese origin.

详细描述

Approximately 250 subjects are planned to be included in the study.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult male or female up to 65 years of age, and of Chinese origin.
  • Moderate (grade 2) or severe (grade 3) glabellar lines at max frown.
  • Prior to and independent of study, subject is seeking long term treatment of their glabellar lines.
  • Prior to and independent of the study participation, physician intended to treat the subject with Dysport.
  • Time and ability to complete the study and comply with instructions.
  • Understands the study requirements and signed the informed consent form (ICF)

排除标准

  • Hypersensitive to Dysport or its excipients.
  • Presence of contraindications to Dysport treatment as specified in the approved leaflet in China.
  • Subject is at risk for precautions, warnings, and/or contraindications to Dysport as specified in the approved leaflet in China.

研究组 & 干预措施

AbobotulinumtoxinA

Participants with moderate to severe GL received a total dose of AbobotulinumtoxinA (Dysport®), 50 U (0.25 mL total; 10 U [0.05 mL per injection site] of study drug into 5 injection sites intramuscularly: 2 injections into each corrugator muscle and 1 injection into the procerus muscle) at Visits 1, 3, and 5.

干预措施: AbobotulinumtoxinA (Biological)

结局指标

主要结局

Percentage of Participants in Each Response Category for Overall Participant Satisfaction at Visit 6, Assessed by the Subject Satisfaction Questionnaire

时间窗: Month 14

The participant's satisfaction with the treatment was assessed using a subject satisfaction questionnaire. At Visit 6 (that is., three weeks, after the 3rd injection) participants were asked "What is your overall satisfaction after three treatment cycles with Dysport?" Participant's response options were noted as: Very Satisfied, Satisfied, Dissatisfied, Very Dissatisfied. Percentage of participants in each response category were reported here.

次要结局

  • Percentage of Participants in Each Response Category for Overall Physician Satisfaction at Visit 6, Assessed by the Physician Satisfaction Questionnaire(Month 14)
  • Percentage of Participants Satisfied With the Treatment Assessed Using a Subject Satisfaction Questionnaire(Month 20)

研究者

发起方
Galderma R&D
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验